HaemaLogiX's CSO, Dr Rosanne Dunn, to speak at Cell and Gene Therapy World Asia, Singapore

We’re pleased to announce that HaemaLogix Chief Scientific Officer Rosanne Dunn has been invited and confirmed to speak at Cell and Gene Therapy World Asia held 14-15 September in Singapore.

HaemaLogiX is one of the few Australian companies represented this year at the conference, which brings together global leaders, visionaries, and pioneers in the field of cell and gene therapy. The conference has a key focus on current best research and development practices, and companies advancing towards manufacturing and commercialisation.

Dr Dunn will speak on the specificity of KMA.CAR T cells against a novel B cell target called kappa myeloma antigen (KMA), drawing on recent preclinical in vivo studies and clinically proven safety data on our other immunotherapy assets.

KMA.CAR T, which is being developed by HaemaLogiX in collaboration with the Peter MacCallum Cancer Centre, is ready to enter a phase I clinical trial for patients with myeloma.

Related information

Visit the Technology and Pipeline pages of this website to learn about KMA.CAR T

An abstract on the target specificity of our immunotherapies was published at the International Conference on Malignant Lymphoma (ICML) in Lugano Switzerland in June.